ArticleThe Journal of clinical investigation2004
Apolipoprotein A-IV inhibits experimental colitis.
Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 149 citations in OpenAlex.
- Persistent immune, coagulation and cardiac dysregulation are correlated with later post-discharge mortality in children with severe malnutrition.BMC medicine · 2026Trial
- Plasma apolipoprotein A-IV deficiency as a proteomics-identified diagnostic biomarker for heat stroke: A prospective 2-center study.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Article
- Proteomics in Cardiovascular Deaths, a Postmortem Pilot Study: The Diagnostic Efficacy of α-1 Antitrypsin and Apolipoprotein A-IV in Ischemic and Congestive Deaths.Diagnostics (Basel, Switzerland) · 2026Article
- Gut Hormones and Inflammatory Bowel Disease.Biomolecules · 2025Review
- The Impact of Cannabidiol (CBD) on Lipid Absorption and Lymphatic Transport in Rats.Nutrients · 2025Article
- Comparative Glycoproteomic Analysis of Mouse 4T1 Breast Cancer Model.Current medicinal chemistry · 2025Article
- Lipid Metabolism Disorders as Diagnostic Biosignatures in Sepsis.Infectious disease reports · 2024Article
- Article
- Interactions Between HDL and CD4+ T Cells: A Novel Understanding of HDL Anti-Inflammatory Properties.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study.BMC cancer · 2024Article
- Article
- Effect of supplementation withFrontiers in microbiology · 2024Article
- Article
- Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes.Diabetology & metabolic syndrome · 2023Article
- HDL anti-inflammatory function is impaired and associated with high SAA1 and low APOA4 levels in aneurysmal subarachnoid hemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- The distinct metabolism between large and small HDL indicates unique origins of human apolipoprotein A4.JCI insight · 2023Article
- Apolipoprotein A-IV of diabetic-foot patients upregulates tumor necrosis factor α expression in microfluidic arterial models.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Allogenic Adipose-Derived Stem Cells in Diabetic Foot Ulcer Treatment: Clinical Effectiveness, Safety, Survival in the Wound Site, and Proteomic Impact.International journal of molecular sciences · 2023Article
- Apolipoprotein A-IV Has Bi-Functional Actions in Alcoholic Hepatitis by Regulating Hepatocyte Injury and Immune Cell Infiltration.International journal of molecular sciences · 2022Article
- Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies.Pharmaceuticals (Basel, Switzerland) · 2022Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
The antiatherogenic properties of apoA-IV suggest that this protein may act as an anti-inflammatory agent. We examined this possibility in a mouse model of acute colitis. Mice consumed 3% dextran sulfate sodium (DSS) in their drinking water for 7 days, with or without daily intraperitoneal injections of recombinant human apoA-IV. apoA-IV significantly and specifically delayed the onset, and reduced the severity and extent of, DSS-induced inflammation, as assessed by clinical disease activity score, macroscopic appearance and histology of the colon, and tissue myeloperoxidase activity. Intravital fluorescence microscopy of colonic microvasculature revealed that apoA-IV significantly inhibited DSS-induced leukocyte and platelet adhesive interactions. Furthermore, apoA-IV dramatically reduced the upregulation of P-selectin on colonic endothelium during DSS-colitis. apoA-IV knockout mice exhibited a significantly greater inflammatory response to DSS than did their WT littermates; this greater susceptibility to DSS-induced inflammation was reversed upon exogenous administration of apoA-IV to knockout mice. These results provide the first direct support for the hypothesis that apoA-IV is an endogenous anti-inflammatory protein. This anti-inflammatory effect likely involves the inhibition of P-selectin-mediated leukocyte and platelet adhesive interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.